...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up.
【24h】

High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up.

机译：三维计算机断层扫描引导的近距离放射治疗的高危和中危前列腺癌：2-8年的随访。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To report post-brachytherapy results in high and intermediate risk patients of prostatic adenocarcinoma.METHODS AND MATERIALS: From June 1994 to June 2000, 356 consecutive high and intermediate risk patients were treated with three-dimensional computed tomography-guided stereotactic pararectal brachytherapy. The age was 42-90 years (median, 68 years), the initial prostate volume was 14-180 cm(3) (median, 59 cm(3)), and initial PSA was 1.7-143 ng/ml (median, 10.5 ng/ml). Three hundred forty-eight patients were available for follow-up for 2 - 8 years (median, 4.5 years). Two hundred eighty patients had one or more high risk factors (PSA >20 ng/ml, Gleason>7, Stage T2b, T3a, or T3b). Sixty-eight patients had only one intermediate risk factor (PSA 10-20 ng/ml or Gleason=7). Patients with both intermediate risks were considered high risk. The high-risk group was further stratified into subgroups with similar risk profile. A dose of 144 Gy with (125)I or 120 Gy with (103)Pd was achieved in 90-100% of the target. Thirty (30) patients (9%) had prior transurethral resection and 229 (64%) were treated with 3 months neoadjuvant androgen ablation.RESULTS: Biochemical disease-free survival was 92% of 280 high risk patients and 96% of 68 intermediate risk patients. Seven patients (2%) required catheterization during the first year for urinary retention, nine patients (3%) required TUR 1-3 years post-implant, three patients (1%) developed grade 1 or 2 incontinence after a second TUR, and four patients (1%) developed grade 3 rectal complications.CONCLUSION: This method produces a high level of biochemical control 2-8 years (median 4.5 years). Morbidity is acceptable regardless of risk profile or initial prostate volume.
机译：目的：报道前列腺癌高危和中危患者近距离放射治疗的结果。方法与材料：1994年6月至2000年6月，连续356例高危和中危患者接受了三维计算机断层扫描引导的立体定向直肠旁直肠近距离放射治疗。年龄为42-90岁（中位数为68岁），初始前列腺体积为14-180 cm（3）（中位数为59 cm（3）），初始PSA为1.7-143 ng / ml（中位数为10.5） ng / ml）。 348例患者接受了2-8年的随访（中位数为4.5年）。 280名患者具有一种或多种高危因素（PSA> 20 ng / ml，格里森> 7，T2b，T3a或T3b期）。 68名患者只有一种中等危险因素（PSA 10-20 ng / ml或Gleason = 7）。具有两种中间风险的患者被认为是高风险的。高风险组进一步分为具有相似风险特征的亚组。在90-100％的靶标中，含（125）I的144 Gy剂量或含（103）Pd的120 Gy剂量。 30例患者（9％）曾行经尿道切除术，229例（64％）接受了3个月的新辅助雄激素消融治疗。结果：280例高危患者中92％的患者无生化疾病，68例中危患者中96％的患者无生化疾病。耐心。第一年有7名患者（2％）需要导尿以保留尿液，植入后1-3年需要9名患者（3％）进行TUR，三名患者（1％）在第二次TUR后出现1级或2级失禁， 4名患者（1％）发生了3级直肠并发症。结论：这种方法在2-8年（中位4.5年）内具有较高的生化控制水平。发病率是可以接受的，与风险状况或初始前列腺体积无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号